The Role of Metformin, Statins and Diet in Men on Active Surveillance for Prostate Cancer

Overview

Journal World J Urol

Specialty Urology

Date 2021 Oct 17

PMID 34657209

Citations 3

Authors

Raj Tiwari

Neil Fleshner

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: A sound scientific basis has been emerging on the anti-neoplastic role of metformin, statins and dietary interventions. However, evidence in prostate cancer patients remains mixed owing to an absence of completed randomized trials. This overview examines the rationale for metformin, statins and dietary intervention for secondary prevention in men on active surveillance by summarizing current evidence base and biological mechanisms in influencing cancer progression and mortality.

Methods: A comprehensive literature search was performed to identify studies that evaluated the role of metformin, statins and diet in the secondary prevention of prostate cancer as well as those that described the anti-cancer mechanisms of these agents. The search included Pubmed, MEDLINE, EMBASE and Cochrane library from inception till August 2021.

Results: A total of 14 trials on metformin, 21 trials on statins and 13 trials on dietary measures were evaluated. Majority were observational population-based cohort studies or meta-analysis of them. Three ongoing prospective randomized controlled trials were also reported. Overall, mixed results were obtained.

Conclusions: The role of metformin and statins remains promising with several trials showing reduced rates of progression and cancer specific mortality. Combination therapy strategies have also been evaluated in more advanced patients showing synergism. Dietary interventions especially fruits, vegetables and fish intake has shown some benefit albeit with mixed results for others like legumes, red meat, coffee and multivitamins. Several ongoing randomized trials will provide stronger evidence in the future for secondary prevention.

Citing Articles

The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy.

Lemos G, Fernandes C, Silva F, Calmasini F Prostate Cancer Prostatic Dis. 2024; 27(2):230-238.

PMID: 38297152 DOI: 10.1038/s41391-024-00793-4.

Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models.

Wang N, Jue T, Holst J, Gunter J BJUI Compass. 2022; 4(1):44-58.

PMID: 36569495 PMC: 9766874. DOI: 10.1002/bco2.187.

Li-Fraumeni Syndrome: Mutation of Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment.

Rocca V, Blandino G, DAntona L, Iuliano R, Di Agostino S Cancers (Basel). 2022; 14(15).

PMID: 35954327 PMC: 9367397. DOI: 10.3390/cancers14153664.

References

Sanda M, Dunn R, Michalski J, Sandler H, Northouse L, Hembroff L . Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358(12):1250-61. DOI: 10.1056/NEJMoa074311. View

Tosoian J, Carter H, Lepor A, Loeb S . Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016; 13(4):205-15. PMC: 4940050. DOI: 10.1038/nrurol.2016.45. View

Sahra I, Le Marchand-Brustel Y, Tanti J, Bost F . Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol Cancer Ther. 2010; 9(5):1092-9. DOI: 10.1158/1535-7163.MCT-09-1186. View

Hankinson S, Fam M, Patel N . A review for clinicians: Prostate cancer and the antineoplastic properties of metformin. Urol Oncol. 2016; 35(1):21-29. DOI: 10.1016/j.urolonc.2016.10.009. View

Dowling R, Zakikhani M, Fantus I, Pollak M, Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67(22):10804-12. DOI: 10.1158/0008-5472.CAN-07-2310. View

Xiang X, Saha A, Wen R, Ruderman N, Luo Z . AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1):161-7. DOI: 10.1016/j.bbrc.2004.06.133. View

Miller R, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum M . Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013; 494(7436):256-60. PMC: 3573218. DOI: 10.1038/nature11808. View

Zhang H, Guo X . Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol. 2016; 78(1):13-26. DOI: 10.1007/s00280-016-3037-3. View

Comstock C, Revelo M, Buncher C, Knudsen K . Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer. 2007; 96(6):970-9. PMC: 2360090. DOI: 10.1038/sj.bjc.6603615. View

10.

Margel D, Urbach D, Lipscombe L, Bell C, Kulkarni G, Austin P . Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013; 31(25):3069-75. DOI: 10.1200/JCO.2012.46.7043. View

11.

Stopsack K, Ziehr D, Rider J, Giovannucci E . Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control. 2015; 27(1):105-13. DOI: 10.1007/s10552-015-0687-0. View

12.

Raval A, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U . Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2015; 18(2):110-21. PMC: 4904224. DOI: 10.1038/pcan.2014.52. View

13.

Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H . Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One. 2014; 9(12):e116327. PMC: 4278883. DOI: 10.1371/journal.pone.0116327. View

14.

Deng D, Yang Y, Tang X, Skrip L, Qiu J, Wang Y . Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis. Diabetes Metab Res Rev. 2015; 31(6):595-602. DOI: 10.1002/dmrr.2645. View

15.

Hamilton R, Freedland S . Rationale for statins in the chemoprevention of prostate cancer. Curr Urol Rep. 2008; 9(3):189-96. DOI: 10.1007/s11934-008-0034-z. View

16.

SCHAFFNER C . Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res. 1981; 75A:279-324. View

17.

Simons K, Ikonen E . Functional rafts in cell membranes. Nature. 1997; 387(6633):569-72. DOI: 10.1038/42408. View

18.

Freeman M, Cinar B, Lu M . Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab. 2005; 16(6):273-9. DOI: 10.1016/j.tem.2005.06.002. View

19.

Zhuang L, Lin J, Lu M, Solomon K, Freeman M . Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 2002; 62(8):2227-31. View

20.

Smith S, Lei Y, Liu J, Cahill M, Hagen G, Barisas B . Luteinizing hormone receptors translocate to plasma membrane microdomains after binding of human chorionic gonadotropin. Endocrinology. 2006; 147(4):1789-95. DOI: 10.1210/en.2005-1046. View